Company Name, Ticker, Customers, else..

Cardiff Oncology Inc (NASDAQ: CRDF)

Sector • Healthcare Industry • Biotechnology & Pharmaceuticals

Industry • Biotechnology & Pharmaceuticals

Sector • Healthcare

Cardiff Oncology Inc 's

Name: Cardiff Oncology Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CRDF Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Cardiff Oncology Inc reported Revenue decrease in the 2 quarter 2026 year on year by -14.05 %, faster than the overall decrease of Cardiff Oncology Inc 's competitors by 0 %, recorded in the same quarter.

• List of CRDF Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Cardiff Oncology Inc recorded a net loss, as well as most of its competitors.

<< CRDF Stock Performance Comparisons

Cardiff Oncology Inc 's Comment on Competition and Industry Peers

The metastatic colorectal cancer (mCRC) treatment landscape includes approved and investigational therapies such as Bristol Myers Squibb's KRAZATI® (adagrasib), which has received accelerated FDA approval for previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer. Clinical trials in mCRC are being conducted by Amgen, Pfizer, Bristol Myers Squibb, and Summit Therapeutics, focusing on targeted and immuno-oncology approaches involving KRAS G12C inhibitors, ID-1/VEGF, and PD-L1/VEGF.

<< See the full list of CRDF competitors

*Market share is calculated based on total revenue.

CRDF's Stock Performance relative to its Competitors

Publicly Traded Peers of Cardiff Oncology Inc

Scholar Rock Holding Corp
Share Performance

+76.51%

One Year

Scholar Rock Holding Corp

Profile

Scholar Rock Holding Corp operates using a business model focused on the development of innovative therapies for the treatment of diseases.

More about Scholar Rock Holding Corp's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 7,056.563 mill.	$ - mill.	$ -408.726 mill.

Iovance Biotherapeutics inc
Share Performance

+250.80%

One Year

Iovance Biotherapeutics inc

Profile

Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.

More about Iovance Biotherapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 3,655.694 mill.	$ 285.608 mill.	$ -353.860 mill.

Intensity Therapeutics Inc
Share Performance

-6.54%

This Quarter

Intensity Therapeutics Inc

Profile

Intensity Therapeutics Inc's business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.

More about Intensity Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 10.826 mill.	$ - mill.	$ -11.163 mill.

Inhibrx Biosciences Inc
Share Performance

+30.58%

This Quarter

Inhibrx Biosciences Inc

Profile

Inhibrx Inc operates using a business model that focuses on the development and commercialization of therapeutics. The company leverages its innovative technology platform to create a diverse pipeline of biologics for the treatment of various diseases. Inhibrx Inc aims to collaborate with strategic partners to advance the development of its pipeline and expand its reach in the healthcare market.

More about Inhibrx Biosciences Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,915.692 mill.	$ - mill.	$ -138.181 mill.

Imagenebio Inc
Share Performance

-9.95%

This Quarter

Imagenebio Inc

Profile

ImageneBio, Inc. develops and commercializes biopharmaceutical products, including IMG-007.

More about Imagenebio Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 59.868 mill.	$ - mill.	$ -47.349 mill.

7 more competitors available

Sources: Cardiff Oncology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Friday, September 4, 2026 10:07 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cardiff Oncology Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.